Barclays PLC increased its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 139.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 222,919 shares of the company's stock after purchasing an additional 129,944 shares during the quarter. Barclays PLC owned 0.26% of Verve Therapeutics worth $1,079,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of VERV. Bank of New York Mellon Corp raised its stake in shares of Verve Therapeutics by 22.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 274,873 shares of the company's stock worth $1,341,000 after buying an additional 49,922 shares during the last quarter. Rhumbline Advisers raised its position in Verve Therapeutics by 12.2% during the second quarter. Rhumbline Advisers now owns 112,446 shares of the company's stock worth $549,000 after acquiring an additional 12,199 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of Verve Therapeutics by 14.1% in the second quarter. Arizona State Retirement System now owns 16,386 shares of the company's stock valued at $80,000 after purchasing an additional 2,019 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Verve Therapeutics in the second quarter valued at approximately $1,183,000. Finally, Daiwa Securities Group Inc. increased its stake in shares of Verve Therapeutics by 89.8% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company's stock worth $59,000 after purchasing an additional 5,723 shares in the last quarter. 97.11% of the stock is currently owned by hedge funds and other institutional investors.
Verve Therapeutics Stock Performance
NASDAQ VERV traded up $0.10 during mid-day trading on Tuesday, reaching $5.64. 927,229 shares of the stock were exchanged, compared to its average volume of 1,365,637. The stock has a market capitalization of $477.50 million, a PE ratio of -2.29 and a beta of 1.71. Verve Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $19.34. The business's fifty day simple moving average is $5.83 and its 200 day simple moving average is $5.68.
Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share for the quarter, topping analysts' consensus estimates of ($0.70) by $0.11. The company had revenue of $6.87 million for the quarter, compared to analyst estimates of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business's revenue for the quarter was up 120.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.72) EPS. On average, analysts anticipate that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.
Analyst Ratings Changes
A number of research firms recently issued reports on VERV. Royal Bank of Canada reduced their target price on Verve Therapeutics from $20.00 to $17.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. HC Wainwright cut their price target on Verve Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group increased their price objective on Verve Therapeutics from $29.00 to $32.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th.
Read Our Latest Stock Analysis on Verve Therapeutics
About Verve Therapeutics
(
Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Featured Stories
Before you consider Verve Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verve Therapeutics wasn't on the list.
While Verve Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
